A decrease in maternal plasma concentrations of sVEGFR-2 precedes the clinical diagnosis of preeclampsia

American Journal of Obstetrics and Gynecology

Volumn 202, Issue 6, 2010, Pages 550.e1-550.e10

  Chaiworapongsa, Tinnakorn ^a,b   Romero, Roberto ^a,b   Tarca, Adi L ^a,c   Kusanovic, Juan Pedro ^a,b   Gotsch, Francesca ^a   Mittal, Pooja ^a,b   Kim, Sun Kwon ^a,b   Vaisbuch, Edi ^a,b   Mazaki Tovi, Shali ^a,b   Erez, Offer ^a,b   Dong, Zhong ^a   Kim, Chong Jai ^a,b   Yeo, Lami ^a,b   Hassan, Sonia S ^a,b  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Wayne State University   (United States)

Author keywords

angiogenesis; biomarker; longitudinal study; mechanisms of disease; pregnancy induced hypertension

Indexed keywords

VASCULOTROPIN RECEPTOR 2;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; FEMALE; GESTATIONAL AGE; HUMAN; MATERNAL PLASMA; PREDICTION; PREECLAMPSIA; PREGNANT WOMAN; PRIORITY JOURNAL;

EID: 77952863949     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2010.04.002     Document Type: Article

References (60)

1. Redman C.W., and Sargent I.L. Latest advances in understanding preeclampsia. Science 308 (2005) 1592-1594
2. Roberts J.M., and Gammill H.S. Preeclampsia: recent insights. Hypertension 46 (2005) 1243-1249
3. Romero R., Lockwood C., Oyarzun E., and Hobbins J.C. Toxemia: new concepts in an old disease. Semin Perinatol 12 (1988) 302-323
4. Sibai B.M. Hypertensive disorders of pregnancy: the United States perspective. Curr Opin Obstet Gynecol 20 (2008) 102-106
5. Maynard S.E., Min J.Y., Merchan J., et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 111 (2003) 649-658
6. Levine R.J., Maynard S.E., Qian C., et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 350 (2004) 672-683
7. Chaiworapongsa T., Romero R., Espinoza J., et al. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia: young investigator award. Am J Obstet Gynecol 190 (2004) 1541-1547
8. Venkatesha S., Toporsian M., Lam C., et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 12 (2006) 642-649
9. Schlembach D., Wallner W., Sengenberger R., et al. Angiogenic growth factor levels in maternal and fetal blood: correlation with Doppler ultrasound parameters in pregnancies complicated by pre-eclampsia and intrauterine growth restriction. Ultrasound Obstet Gynecol 29 (2007) 407-413
10. Espinoza J., Romero R., Nien J.K., et al. Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor. Am J Obstet Gynecol 196 (2007) 326-13
11. Lindheimer M.D., and Romero R. Emerging roles of antiangiogenic and angiogenic proteins in pathogenesis and prediction of preeclampsia. Hypertension 50 (2007) 35-36
12. Romero R., Nien J.K., Espinoza J., et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med 21 (2008) 9-23
13. Crispi F., Llurba E., Dominguez C., Martin-Gallan P., Cabero L., and Gratacos E. Predictive value of angiogenic factors and uterine artery Doppler for early- versus late-onset pre-eclampsia and intrauterine growth restriction. Ultrasound Obstet Gynecol 31 (2008) 303-309
14. Sibai B.M., Koch M.A., Freire S., et al. Serum inhibin A and angiogenic factor levels in pregnancies with previous preeclampsia and/or chronic hypertension: are they useful markers for prediction of subsequent preeclampsia?. Am J Obstet Gynecol 199 (2008) 268-269
15. Gotsch F., Romero R., Kusanovic J.P., et al. Preeclampsia and small-for-gestational age are associated with decreased concentrations of a factor involved in angiogenesis: soluble Tie-2. J Matern Fetal Neonatal Med 21 (2008) 389-402
16. Haddad R., Romero R., Gould B.R., et al. Angiogenesis gene expression in mouse uterus during the common pathway of parturition. Am J Obstet Gynecol 198 (2008) 539-8
17. Toft J.H., Lian I.A., Tarca A.L., et al. Whole-genome microarray and targeted analysis of angiogenesis-regulating gene expression (ENG, FLT1, VEGF, PlGF) in placentas from pre-eclamptic and small-for-gestational-age pregnancies. J Matern Fetal Neonatal Med 21 (2008) 267-273
18. Stepan H. Angiogenic factors and pre-eclampsia: an early marker is needed. Clin Sci (Colch) 116 (2009) 231-232
19. Ferrara N., Gerber H.P., and LeCouter J. The biology of VEGF and its receptors. Nat Med 9 (2003) 669-676
20. Shibuya M. Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis. BMB Rep 41 (2008) 278-286
21. Gerber H.P., McMurtrey A., Kowalski J., et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway: requirement for Flk-1/KDR activation. J Biol Chem 273 (1998) 30336-30343
22. McKeeman G.C., Ardill J.E., Caldwell C.M., Hunter A.J., and McClure N. Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia develop. Am J Obstet Gynecol 191 (2004) 1240-1246
23. Chaiworapongsa T., Romero R., Kim Y.M., et al. Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J Matern Fetal Neonatal Med 17 (2005) 3-18
24. Park C.W., Park J.S., Shim S.S., Jun J.K., Yoon B.H., and Romero R. An elevated maternal plasma, but not amniotic fluid, soluble fms-like tyrosine kinase-1 (sFlt-1) at the time of mid-trimester genetic amniocentesis is a risk factor for preeclampsia. Am J Obstet Gynecol 193 (2005) 984-989
25. Stepan H., Geipel A., Schwarz F., Kramer T., Wessel N., and Faber R. Circulatory soluble endoglin and its predictive value for preeclampsia in second-trimester pregnancies with abnormal uterine perfusion. Am J Obstet Gynecol 198 (2008) 175-176
26. Savvidou M.D., Noori M., Anderson J.M., Hingorani A.D., and Nicolaides K.H. Maternal endothelial function and serum concentrations of placental growth factor and soluble endoglin in women with abnormal placentation. Ultrasound Obstet Gynecol 32 (2008) 871-876
27. Unal E.R., Robinson C.J., Johnson D.D., and Chang E.Y. Second-trimester angiogenic factors as biomarkers for future-onset preeclampsia. Am J Obstet Gynecol 197 (2007) 211-214
28. Vatten L.J., Eskild A., Nilsen T.I., Jeansson S., Jenum P.A., and Staff A.C. Changes in circulating level of angiogenic factors from the first to second trimester as predictors of preeclampsia. Am J Obstet Gynecol 196 (2007) 239-246
29. Erez O., Romero R., Espinoza J., et al. The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age. J Matern Fetal Neonatal Med 21 (2008) 279-287
30. Koga K., Osuga Y., Yoshino O., et al. Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. J Clin Endocrinol Metab 88 (2003) 2348-2351
31. Masuyama H., Suwaki N., Nakatsukasa H., Masumoto A., Tateishi Y., and Hiramatrsu Y. Circulating angiogenic factors in preeclampsia, gestational proteinuria, and preeclampsia superimposed on chronic glomerulonephritis. Am J Obstet Gynecol 194 (2006) 551-556
32. Robinson C.J., Johnson D.D., Chang E.Y., Armstrong D.M., and Wang W. Evaluation of placenta growth factor and soluble Fms-like tyrosine kinase 1 receptor levels in mild and severe preeclampsia. Am J Obstet Gynecol 195 (2006) 255-259
33. Woolcock J., Hennessy A., Xu B., et al. Soluble Flt-1 as a diagnostic marker of pre-eclampsia. Aust N Z J Obstet Gynaecol 48 (2008) 64-70
34. Wikstrom A.K., Larsson A., Eriksson U.J., Nash P., Norden-Lindeberg S., and Olovsson M. Placental growth factor and soluble FMS-like tyrosine kinase-1 in early-onset and late-onset preeclampsia. Obstet Gynecol 109 (2007) 1368-1374
35. Ebos J.M., Bocci G., Man S., et al. A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma. Mol Cancer Res 2 (2004) 315-326
36. Millauer B., Longhi M.P., Plate K.H., et al. Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Res 56 (1996) 1615-1620
37. Lin P., Sankar S., Shan S., et al. Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor. Cell Growth Differ 9 (1998) 49-58
38. Tseng J.F., Farnebo F.A., Kisker O., et al. Adenovirus-mediated delivery of a soluble form of the VEGF receptor Flk1 delays the growth of murine and human pancreatic adenocarcinoma in mice. Surgery 132 (2002) 857-865
39. Becker C.M., Farnebo F.A., Iordanescu I., et al. Gene therapy of prostate cancer with the soluble vascular endothelial growth factor receptor Flk1. Cancer Biol Ther 1 (2002) 548-553
40. McLeod D.S., Taomoto M., Cao J., Zhu Z., Witte L., and Lutty G.A. Localization of VEGF receptor-2 (KDR/Flk-1) and effects of blocking it in oxygen-induced retinopathy. Invest Ophthalmol Vis Sci 43 (2002) 474-482
41. Tas F., Duranyildiz D., Oguz H., Camlica H., Yasasever V., and Topuz E. Circulating serum levels of angiogenic factors and vascular endothelial growth factor receptors 1 and 2 in melanoma patients. Melanoma Res 16 (2006) 405-411
42. Cortelezzi A., Fracchiolla N.S., Mazzeo L.M., et al. Endothelial precursors and mature endothelial cells are increased in the peripheral blood of myelodysplastic syndromes. Leuk Lymphoma 46 (2005) 1345-1351
43. Aref S., El Sherbiny M., Goda T., Fouda M., Al Askalany H., and Abdalla D. Soluble VEGF/sFLt1 ratio is an independent predictor of AML patient out come. Hematology 10 (2005) 131-134
44. Faderl S., Do K.A., Johnson M.M., et al. Angiogenic factors may have a different prognostic role in adult acute lymphoblastic leukemia. Blood 106 (2005) 4303-4307
45. Robak E., Sysa-Jedrzejewska A., and Robak T. Vascular endothelial growth factor and its soluble receptors VEGFR-1 and VEGFR-2 in the serum of patients with systemic lupus erythematosus. Mediators Inflamm 12 (2003) 293-298
46. Srikiatkhachorn A., Ajariyakhajorn C., Endy T.P., et al. Virus-induced decline in soluble vascular endothelial growth receptor 2 is associated with plasma leakage in dengue hemorrhagic fever. J Virol 81 (2007) 1592-1600
47. Kim S.Y., Park S.Y., Kim J.W., et al. Circulating endothelial progenitor cells, plasma VEGF, VEGFR-1 and VEGFR-2 levels in preeclampsia. Am J Obstet Gynecol 193 Suppl (2005) S74
48. Wallner W., Sengenberger R., Strick R., et al. Angiogenic growth factors in maternal and fetal serum in pregnancies complicated by intrauterine growth restriction. Clin Sci (Colch) 112 (2007) 51-57
49. Chaiworapongsa T., Romero R., Gotsch F., et al. Low maternal concentrations of soluble vascular endothelial growth factor receptor-2 in preeclampsia and small for gestational age. J Matern Fetal Neonatal Med 21 (2008) 41-52
50. Sibai B.M., Ewell M., Levine R.J., et al. Risk factors associated with preeclampsia in healthy nulliparous women: the calcium for preeclampsia prevention (CPEP) study group. Am J Obstet Gynecol 177 (1997) 1003-1010
51. von D.P., Magee L.A., and Roberts J.M. Subclassification of preeclampsia. Hypertens Pregnancy 22 (2003) 143-148
52. Alexander G.R., Himes J.H., Kaufman R.B., Mor J., and Kogan M. A United States national reference for fetal growth. Obstet Gynecol 87 (1996) 163-168
53. Ebos J.M., Lee C.R., Bogdanovic E., et al. Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth. Cancer Res 68 (2008) 521-529
54. Ebos J.M., Lee C.R., Christensen J.G., Mutsaers A.J., and Kerbel R.S. Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci U S A 104 (2007) 17069-17074
55. Drevs J., Zirrgiebel U., Schmidt-Gersbach C.I., et al. Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials. Ann Oncol 16 (2005) 558-565
56. Norden-Zfoni A., Desai J., Manola J., et al. Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin Cancer Res 13 (2007) 2643-2650
57. DePrimo S.E., Bello C.L., Smeraglia J., et al. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med 5 (2007) 32
58. Bosio P.M., Wheeler T., Anthony F., Conroy R., O'herlihy C., and McKenna P. Maternal plasma vascular endothelial growth factor concentrations in normal and hypertensive pregnancies and their relationship to peripheral vascular resistance. Am J Obstet Gynecol 184 (2001) 146-152
59. Kupferminc M.J., Daniel Y., Englender T., et al. Vascular endothelial growth factor is increased in patients with preeclampsia. Am J Reprod Immunol 38 (1997) 302-306
60. Sharkey A.M., Cooper J.C., Balmforth J.R., et al. Maternal plasma levels of vascular endothelial growth factor in normotensive pregnancies and in pregnancies complicated by pre-eclampsia. Eur J Clin Invest 26 (1996) 1182-1185